An observational study in Autoimmune Encephalitis, LGI1 Encephalitis and Limbic Encephalitis, sponsored by Shen Chun-Hong. Completed at 1 site in China. Per ClinicalTrials.gov, last updated 2026-07-23.
Sponsored by Shen Chun-Hong · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Autoimmune Diseases of the Nervous System with a site in China — 18 open to participants now, 20 under way, 3 of them phase 3. Autoimmune Diseases of the Nervous System · China.
Among the 26 studies in Autoimmune Diseases of the Nervous System with a site in China, this one is the 10th largest by enrollment of the 13 observational ones that give a count, is the only one that started in 2015, is one of 13 observational ones, and was the 20th registered.
123 studies on the registry are indexed under Autoimmune Diseases of the Nervous System; 59 are open to participants now.
Browse Autoimmune Diseases of the Nervous System studies →18 of the 26 studies in Autoimmune Diseases of the Nervous System with a site in China are open now. Recruiting first, the newest first:
Beijing Tongren Hospital · Sites in China
Ages 18+
Tongji Hospital · Sites in China
Ages 18–75
Tongji Hospital · Sites in China
Ages 18–70
Tianjin Huanhu Hospital · Sites in China
Ages 18+
Tongji Hospital · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 44 Autoimmune Diseases of the Nervous System studies recruiting now, 27 (61%) set no upper age limit and 11 (25%) stop at 75 or younger; 15 take children under 18; 9 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 112 is below the median of 160 across 57 observational studies indexed under Autoimmune Diseases of the Nervous System.
Median enrollment 36 across the 13 interventional studies, 300 across the 13 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 26 have an industry lead sponsor. The 10 most frequent:
Shen Chun-Hong is the lead sponsor of 4 studies on the registry; 3 are open to participants now.
Shen Chun-Hong has 3 studies filed under Autoimmune Diseases of the Nervous System — fewer than ten, so there is no comparison to draw.
6 of the studies in Autoimmune Diseases of the Nervous System with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05503264Phase 3Hoffmann-La RocheA Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis | 2026-12-16 |
| NCT07337785Tongji HospitalCD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases | 2026-12-01 |
| NCT06388161Shen Chun-HongNeural Autoantibody Prevalence in New-onset Focal Seizures of Unknown Etiology | 2026-12-31 |
| NCT06797024Tongji HospitalJY231 Injection for the Treatment of Relapsed/Refractory Neurologic Immune Disorders | 2026-12-31 |
| NCT04561557Tongji HospitalSafety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System | 2027-02-22 |
Add all 6 to your calendar (.ics) → With an account.
Among the 26 studies in Autoimmune Diseases of the Nervous System with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study focuses on a rare brain disease called anti-leucine-rich glioma-inactivated 1 (LGI1) encephalitis. In this condition, the body's immune system mistakenly attacks a protein in the brain, which can cause problems with memory, thinking, behavior, and seizures. While most patients get better with initial treatments, some continue to have long-term symptoms or experience a return of the disease (called a "relapse") months or years later. The goal of this study is to understand how often these relapses and long-term problems happen and to identify which patients are most at risk.
The investigators will look back at the medical records of patients diagnosed with anti-LGI1 encephalitis at five major hospitals in Eastern China. The information about their symptoms, the treatments they received and how they recovered over time are obtained. Then, the investigators will analyze this information to find out what factors are linked to having a relapse or a poor long-term recovery.
By understanding the risks for relapse and poor outcomes, doctors can better identify which patients need closer monitoring and more long-term treatment strategies. The results of this study will help create better guidelines for managing patients with this disease after their initial recovery, aiming to improve their quality of life in the long run.
Study Background:
Anti-LGI1 encephalitis is an autoimmune disorder where the body produces antibodies that attack the brain, leading to symptoms like memory loss, psychiatric issues, and seizures. Initial treatments with immunotherapy (like steroids) are effective for most patients. However, a significant number of patients are left with lasting neurological problems, and some experience a return of the disease (relapse) after a period of improvement. The rates of relapse and poor long-term outcomes reported in previous studies vary widely, and it is not clear which patients are most vulnerable. Furthermore, the best strategy for long-term treatment after the initial phase to prevent relapses is not well-established.
Study Objectives
This study aims to:
Data Collection
Data was gathered from electronic medical records and, when necessary, follow-up phone interviews. The information collected includes:
Outcome Definitions
patients at five tertiary medical centers from four cities in Eastern China (Second Affiliated Hospital of Zhejiang University School of Medicine, Sir Run Run Shaw Hospital of Zhejiang University School of Medicine, Shaoxing People's Hospital, Ningbo Medical Center Lihuili Hospital, and Huzhou Third People's Hospital)
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapse
the presence of new or worsening clinical features after at least 3 months of stability or improvement
Time frame: Through study completion, with the last follow-up date in January 2026
Functional outcomes
an mRS score at the last follow-up ≤ 2 indicated good outcome, while an mRS score \> 2 indicated poor outcome
Time frame: Through study completion, with the last follow-up date in January 2026
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Jan 2015 to primary completion in Jan 2026, 132 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Autoimmune Diseases of the Nervous System →
Shen Chun-Hong